TrialThe New England journal of medicine2023
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.
Toni K Choueiri et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
103 papers cite itlatest 60 shown
this paperpooled ittrialcites it